IL-13

Class

Anti-IL-13 monoclonal antibody

Interleukin-13 (IL-13) is a signaling protein, or cytokine, produced mainly by a subset of immune cells called type 2 helper T cells and related innate lymphoid cells. It acts on epithelial cells, smooth muscle, and fibroblasts in the skin, lungs, and gut, driving hallmark features of allergic inflammation: excess mucus production, tissue remodeling, impaired skin barrier function, and heightened tissue reactivity. Because IL-13 sits near the center of this type 2 inflammatory pathway, blocking it before it engages its receptor can dampen the downstream cascade that produces symptoms in diseases such as atopic dermatitis, asthma, and related allergic conditions. Monoclonal antibodies that bind and neutralize circulating IL-13 prevent it from activating its receptor complex on target cells, reducing the inflammatory signals that perpetuate itching, airway narrowing, and tissue damage. Engineering such antibodies for extended half-life allows the drug to remain active in circulation longer, so fewer injections are needed to maintain continuous suppression of the cytokine. This approach is one of several targeting the type 2 inflammatory axis, alongside agents that act on related cytokines or their shared receptor components, reflecting the broader therapeutic strategy of interrupting allergic inflammation at different points along the same pathway.